Iceland’s #1 Dating App, Smitten, Raises $10M Series A From Makers Fund, Possible Ventures and More to Woo Gen Z-ers Globally With Its Fresh Approach to Dating
15.9.2022 14:01:00 EEST | Business Wire | Press release
Dating app Smitten has raised a $10M Series A from Makers Fund, Possible Ventures, Wonder Invest and current shareholders ByFounders, ProFounders, Tennin, and Smitten's board member and Vivino founder Heini Zachariassen. Smitten, the most popular dating app in Iceland and the second most popular in Denmark, will use the financing to grow its team and to expand to new markets as they woo Gen Zers with their fresh, gamified approach to dating.
“My co-founder, Asgeir, and I share an intense interest in how people connect and communicate,” says David Simonarson, Smitten Co-Founder and CEO. “After years of creating social consumer apps, we fell in love with the online dating space and launched Smitten in 2020. We created personality-based games and fun interactive profiles to make it easy for strangers to form meaningful connections. Seeing how much our users love Smitten, we believe we can become the leading player in online dating for Generation Z.”
Smitten is founded by David Simonarson, CEO, and Asgeir Visir, Designer, and was released by the founders and its CTO, Magnus Olafsson. Smitten mixes games, entertainment, and flirting to jumpstart conversations and help users engage more seamlessly. Smitten's fun and creative approach to dating has struck a chord with Gen Zers, proven by the app’s more than 200 million swipes to date and whopping 30%+ stickiness rate. Most dating apps leave people to convert a match into a conversation with awkward starts that lead nowhere. Smitten makes getting into a conversation as easy as swiping through use of games, interactive profiles and icebreakers. Smitten gets users into fun, quality conversations regardless of their conversation skills, and has found that more than 60% of Smitten matches result in a post-match interaction vs 11% on industry-leading app, Tinder*.
The key to Smitten’s post-match interactions are mini-games people can play on each other’s profiles. “Our questionnaire game, Guessary, allows you to get to know the other person you are viewing by guessing how they answered a series of Yes-and-No questions,” explained Asgeir Visir, Smitten Co-Founder and Designer. “You could be answering questions like ‘Have they ever been arrested?’ or ‘Do they like pineapple on their pizza?’ and you would get immediate feedback if you answered correctly or not. Another fun game, Lie Detector, is inspired by the age-old social game Two Truths and Lie, where people add three statements about themselves to their profile, and you have one chance to spot the lie. These games are designed for users to get to know the person they are viewing before deciding if they want to like them or not. And the beautiful part is when you match with someone, the results of the games are posted in the chat and act as an icebreaker, making it so much easier to initiate a fun conversation.”
“Social discovery and gaming is an increasingly interesting intersection, and the team at Smitten have created an amazingly fun experience that truly strikes a chord with young adults,” said Alli Ottarson, Makers' lead on the deal. “Having spent time building a strong relationship with the founders David and Ásgeir, we have been privileged to a front row seat to follow Smitten´s success. We share a common vision for how the next generation will meet and interact, and we’re thrilled to be a part of the Smitten journey."
To learn more about Smitten, please visit smittendating.com.
ABOUT SMITTEN
Smitten is on a mission to make the most fun dating app in the world. Through creative, unique profile games and entertaining content, Smitten transforms how people view online dating. While operating at the intersection of dating, gaming, and entertainment, Smitten gives its users superpowers by making it as easy as swiping to get into a fun and meaningful conversation. Smitten outperforms the industry-leading dating app regarding post-match interactions, with more than 60% of matches progressing to some interaction. Smitten is founded in Iceland by co-founders David Orn Simonarson, CEO, and Asgeir Visir, UX Designer. The seasoned duo has been working together creating social apps to connect people for the past ten years. The team's mission is to create the most fun dating app in the world.
*per research at https://arxiv.org/abs/1607.01952
About Makers Fund
Makers Fund is a global interactive entertainment venture capital firm focused on early-stage investments. Makers is dedicated to furthering growth and innovation in the interactive entertainment industry. With more than 90 portfolio companies to date, Makers provides founders strategic value that is deeply catered to companies across the value chain in the industry. For more information, visit makersfund.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220915005317/en/
Contact information
Sibel Sunar
fortyseven communications for Smitten
makersfund@fortyseven.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 21:00:00 EET | Press release
Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 21:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 17:00:00 EET | Press release
Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260328320362/en/ Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5 The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8 “Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development
Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 21:56:00 EET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 19:46:00 EET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom